Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by TheMadMonkon Aug 23, 2023 5:12pm
322 Views
Post# 35602709

Concentration

ConcentrationIt is going to be interesting to watch what happens to the stock price of ATE if and when we have positive results from P2 next spring.  Over the last two years there has been significant concentration in the shareholder base.  With virtually no new investors in the last two years, 10-20% of the outstanding shares have been sold by smaller short-term shareholders and scooped up by larger long-term shareholders.  Plus with the cancelation of millions of warrants, there is even less supply weighing down the stock price.  If this stock starts to run, after results are released there could be explosive torque in this name since there will be much fewer shares available for sale.  We saw an example of this the last two weeks with very low volume, the stock price rose approximately 32% from 46 cents to 61 cents with just a small amount of buying interest.  What would happen if investors tried to purchase half a million or a million shares?
<< Previous
Bullboard Posts
Next >>